Samia Mora, MD, MHS
Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women’s Hospital
smora@bwh.harvard.edu
Dr. Mora is a cardiovascular medicine specialist at the Brigham and Women’s Hospital, where she is the Director of the Center for Lipid Metabolomics. She has joint appointments in the Divisions of Preventive Medicine, Cardiovascular Medicine, and Women’s Health. Dr. Mora received her undergraduate degree from Harvard University, and her medical degree from Harvard Medical School. She completed an internal medicine residency at Massachusetts General Hospital and a cardiovascular disease fellowship at The Johns Hopkins Hospital, where she also obtained a Masters in Health Science (Epidemiology) from the Johns Hopkins Bloomberg School of Public Health. She is board certified in cardiovascular disease and echocardiography, and is a Fellow of the American Heart Association, American College of Cardiology, and American Society of Echocardiography. She also serves on the Editorial Boards of JAMA Internal Medicine and Atherosclerosis. Dr. Mora’s clinical interests include cardiovascular prevention, lipids, modifiable risk factors, and women’s health. The author of over 150 peer-reviewed publications, Dr. Mora’s research focuses on risk factors and prevention of cardiovascular disease. She is actively involved with several randomized clinical trials and observational studies, having served on the Endpoints Committee of the Women’s Health Study, the Clinical Coordinating Committee of the JUPITER trial, the Steering Committee of the VITAminD and OmegA-3 Trial (VITAL), and the Harvard Investigator on the Gulf Population Risks and Epidemiology of Vascular Events and Treatment (Gulf PREVENT) study. Dr. Mora recently co-developed (with Dr. Manson and Mr. Ames) the free Aspirin-Guide mobile app for aspirin in primary prevention of cardiovascular disease (available for iPhone, iPad, Android, and on the web on www.aspiringuide.com). Dr. Mora is an Elected Member of the Association for University Cardiologists and the American Society for Clinical Investigation.
AB: Harvard University
MD: Harvard Medical School
MHS: Johns Hopkins Bloomburg School of Public Health
Full Listing of Publications
- Mapping sidewalk accessibility with smartphone imagery and Visual AI: a participatory approach November 13, 2024Evaluating sidewalk accessibility is conventionally a manual and time-consuming task that requires specialized personnel. While recent developments in Visual AI have paved the way for automating data analysis, the lack of sidewalk accessibility datasets remains a significant challenge. This study presents the design and validation of Sidewalk AI Scanner, a web app that enables quick, […]Diego Morra
- Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial November 3, 2024CONCLUSIONS: Each of insulin, C-peptide, IRS, and HbA1c were associated with incident T2D with the strongest association noted for HbA1c. While HbA1c was significantly associated with CVD risk, a novel IRS appears to be associated with CHD risk. Neither vitamin D nor n-3 FA modified the associations between these biomarkers and cardiometabolic outcomes.Frank Qian
- Hypoparathyroidism: an update on new therapeutic approaches October 13, 2024BACKGROUND: Hypoparathyroidism is a rare endocrine disease characterized by insufficient parathyroid hormone (PTH) secretion by the parathyroid glands, leading to hypocalcemia. In contrast to most hormone deficiencies for which hormone replacement is currently the mainstay of therapy, hypoparathyroidism has conventionally been treated with calcium supplements and active analogs of vitamin D. Although the advent of […]Marco Pitea
- Tailoring Risk Prediction Models to Local Populations September 18, 2024CONCLUSIONS AND RELEVANCE: The interpretable ML approach presented in this article enhanced the accuracy of the AHA-PREVENT model when applied to a local population while still preserving the risk associations found by the original model. This method has the potential to recalibrate other established risk tools and is implementable in electronic health record systems for […]Aniket N Zinzuwadia
- Plasma Levels of Polyols Erythritol, Mannitol, and Sorbitol and Incident Coronary Heart Disease Among Women September 4, 2024CONCLUSIONS: Higher plasma erythritol and mannitol/sorbitol were related to elevated risks of CHD even after adjustment for diet, lifestyles, adiposity, and other risk factors. The unfavorable association of mannitol/sorbitol, but not erythritol, with CHD risk remained significant independently of diabetes/hyperglycemia.Yoriko Heianza